MetaCap

Novo Nordisk A/S (NVO) vs Takeda Pharmaceutical (TAK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Takeda Pharmaceutical (TAK) has outperformed Novo Nordisk A/S (NVO) over the past year, gaining 52.2% versus a loss of 20.6%. Over five years, TAK leads with a +60.9% price change compared with -30.1% for NVO. Novo Nordisk A/S is the larger company by market cap ($166.69 billion vs $69.55 billion), about 2.4 times the size.

On valuation, Novo Nordisk A/S trades at a lower forward P/E (10.8x vs 41.1x for Takeda Pharmaceutical). Takeda Pharmaceutical offers the higher dividend yield (927.88% vs 30.94%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NVO-20.60%TAK+52.24%
+56%+13%-30%
Nov 21, 20251 yearNov 20, 2026
NVO-33.57%TAK+55.39%
+160%+57%-46%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NVO versus TAK key metrics
MetricNVOTAK
Share price$37.82$21.77
Market cap$166.69B$69.55B
1-day change-2.70%+1.68%
YTD return-25.67%+39.64%
1-year return-20.60%+52.24%
5-year return-30.07%+60.90%
P/E ratio (TTM)9.55311.00
Forward P/E10.7741.08
EPS (TTM)$3.96$0.07
Dividend yield30.94%927.88%
Annual dividend$11.70$202.00
52-week high$64.16$22.07
52-week low$35.12$14.16
Distance from 52-week high-41.05%-1.36%
Analyst consensusholdstrong_buy
Avg. price target upside+20.28%+12.68%
Average volume12.59M2.73M
Shares outstanding3.33B3.19B
Employees68,79447,029
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Novo Nordisk A/S is about 2.4 times larger than Takeda Pharmaceutical by market value ($166.69B vs $69.55B).
  • TAK has outperformed NVO by 72.8 percentage points over the past year.
  • Takeda Pharmaceutical trades at a higher earnings multiple (311.0x vs 9.6x trailing P/E).
  • Takeda Pharmaceutical offers a meaningfully higher dividend yield (927.88% vs 30.94%).

About Novo Nordisk A/S

NVO stock →

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 68,794 employees

About Takeda Pharmaceutical

TAK stock →

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.

Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees

NVO vs TAK FAQ

Which is bigger, Novo Nordisk A/S or Takeda Pharmaceutical?

Novo Nordisk A/S (NVO) is larger, with a market capitalization of $166.69B compared with $69.55B for Takeda Pharmaceutical (TAK).

Which stock has performed better over the past year, NVO or TAK?

TAK returned +52.24% over the past 12 months, compared with -20.60% for NVO (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, NVO or TAK?

NVO has the lower trailing P/E at 9.6, versus 311.0 for TAK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Novo Nordisk A/S or Takeda Pharmaceutical?

Takeda Pharmaceutical has the higher yield at 927.88%, compared with 30.94% for Novo Nordisk A/S.

Are Novo Nordisk A/S and Takeda Pharmaceutical in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons